FARMINGTON, Conn.—A new report makes predictions about the growth of the nonvascular stent market, including ureteral, biliary, pancreatic, esophageal, bronchial and tracheal stents. The $185 million U.S. market for nonvascular stents will grow moderately over the next five years at a rate averaging just under five percent per year, according to the report.
The colonic, duodenal/pyloric and prostatic segments will grow much more dramatically, with each of them yielding more than 15 percent average annual revenue growth through 2015, according to the report, "US Markets for Nonvascular Stents 2011." It was presented by Global Information, Inc., and was conducted by Millennium Research Group, a market research company.
The report summary is as follows:
“A key driver of the growth in colonic and duodenal/pyloric stents will be in the treatment of unresectable colon cancer, which is increasing in incidence and cannot be treated with surgery. Rising physician awareness of the benefits of stenting over open surgery in general will increase demand. These benefits include less invasive treatment, higher success rates and fewer complications. Product innovations such as easier-to-deploy and covered self-expanding metal stents (SEMS) will also help drive market growth.
“The US market for colonic and duodenal/pyloric stents is dominated by Boston Scientific. Cook Medical holds a much smaller share of this market, but will aim to increase its presence with the recently approved Evolution Controlled-Release Colonic and Duodenal Stent System products, which is designed to reduce the risk of perforation and migration. Other possible new SEMS competitors are M.I. Tech and Taewoong Medical, which have versions available in other countries and are expected to receive Food and Drug Administration approval for these devices as early as late 2011.
“The report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for ureteral, biliary and pancreatic, esophageal, colonic and duodenal/pyloric, bronchial and tracheal and prostatic stents in the United States.”
Source: Global Information, Inc.